International news in seven languages
Topic
A new analysis suggests mammograms may lead to far less breast cancer overdiagnosis than some earlier studies indicated. Researchers reexamined all eight major randomized screening trials and accounted for differences in follow-up time, screening frequency, and screening after trials ended. Their results were consistent with an overdiagnosis rate below 5%, rather than estimates approaching 30% to 50%.
Linc offers sessions online or in-person at The Forum in Gloucester to patients at any stage in their diagnosis, as well as their loved ones.
A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored drug sensitivity in resistant lung cancer cells, and slowed tumor growth in animal models.
Becky Jones is among the more than 40 people who have taken legal action against the board of directors of a central England hospital.
Maya, 13, from Hythe in Kent, was diagnosed with neuroblastoma when she was three.
Cancer rates are rising in adults under 55, and new research suggests accelerated biological aging may be one piece of the puzzle. Scientists found that people from more recent generations tended to have bodies that appeared biologically older than those of earlier generations at the same chronological age. Greater biological age acceleration was linked to a higher risk of early onset cancers, with specific patterns seen for lung, gastrointestinal, uterine and colorectal cancers.
Patients in England with an incurable breast cancer can now access a life-extending drug on the NHS, two years after it was deemed too expensive by a health body.
Scientists are testing a counterintuitive way to fight mesothelioma, an aggressive asbestos-linked cancer with few effective treatments. A new experimental mesothelioma drug kills cancer cells by disabling PRX3, an antioxidant defense that tumors use to survive intense oxidative stress. In an early clinical trial, it controlled disease progression in 67% of patients and produced encouraging survival results, raising hopes that the strategy could eventually be used against other cancers.
Cancer care has got worse since the government announced plans to speed up waiting times and save more lives, BBC analysis shows.
Enhertu, which can give patients an extra seven months to live on average, has been prescribed in Scotland for more than two years and is available.
